Related Experiment Video

Updated: Feb 14, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.8K

Intrinsic changes of left ventricular function in patients with Behçet disease and comparison according to systemic

Byung Joo Sun1, Jae-Hyeong Park1, Su-Jin Yoo2

  • 1Division of Cardiology, Department of Internal Medicine, School of Medicine, Chungnam National University, Chungnam National University Hospital, Daejeon, Korea.

Echocardiography (Mount Kisco, N.Y.)
|February 17, 2018
PubMed

Insights

Behçet disease (BD) patients show reduced heart function (GLS) even without routine echocardiogram abnormalities. This cardiac dysfunction in BD is present regardless of systemic disease activity.

Area of Science:

  • Cardiology
  • Rheumatology
  • Internal Medicine

Background:

  • Behçet disease (BD) is a multisystem inflammatory disorder.
  • Cardiac involvement in BD is known but often diagnosed late.
  • Early detection of cardiac manifestations is crucial for patient management.

Purpose of the Study:

  • To identify early cardiac manifestations in Behçet disease patients.
  • To classify systemic BD activity and correlate it with cardiac findings.
  • To investigate subclinical cardiac dysfunction in BD.

Main Methods:

  • Prospective study of 85 BD patients without prior heart disease.
  • Speckle tracking echocardiography used for assessment.
  • Analysis of left ventricular global longitudinal strain (GLS) and ejection fraction (LVEF).
  • Comparison with 145 age- and gender-matched controls.
  • BD patients categorized by systemic activity: minimal, controlled, active.

Main Results:

  • 81 BD patients analyzed; mean LVEF was normal (64±5%).
  • BD patients showed significantly reduced GLS compared to controls (-17.1±2.9% vs -20.8±2.2%).
  • Reduced GLS was observed across all systemic BD activity groups (minimal, controlled, active).
  • No significant difference in cardiac manifestations based on systemic BD activity level.

Conclusions:

  • Behçet disease patients exhibit intrinsic left ventricular dysfunction.
  • This dysfunction is detectable via GLS even with normal LVEF on routine echocardiography.
  • Cardiac manifestations in BD are not directly proportional to systemic disease activity.
Abstract

Keywords:
Behçet diseaseechocardiographyleft ventricular dysfunction

More Related Videos

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography06:34

Evaluation of Left Ventricular Structure and Function using 3D Echocardiography

Published on: October 28, 2020

4.7K
Echocardiographic Characterization of Left Ventricular Structure, Function, and Coronary Flow in Neonate Mice07:55

Echocardiographic Characterization of Left Ventricular Structure, Function, and Coronary Flow in Neonate Mice

Published on: April 7, 2022

3.8K

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
210
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
2.5K
Intrinsically Disordered Proteins02:18

Intrinsically Disordered Proteins

Intrinsically disordered proteins are a group of proteins that do not fold into specific three-dimensional structures. Their structural flexibility allows them to complement ordered proteins to perform functions that are inaccessible to rigid structures. They are more common in eukaryotes than prokaryotes and may either be exclusively intrinsically disordered or hybrid proteins, consisting of a mix of ordered and disordered regions. The absence of a rigid structure in these proteins can be...
19.6K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
987